Papillon-Lefèvre syndrome (PLS) is a rare autosomal-recessive genodermatosis characterized by palmoplantar hyperkeratosis and severe early-onset periodontitis. The development of malignant cutaneous neoplasms within the hyperkeratotic lesions of the syndrome is quite rare. Here, we report on a 51-year-old Japanese woman with PLS associated with recurrent malignant melanoma (MM). Mutation analysis of the cathepsin C gene revealed that the proband was homozygous for a missense mutation, c.415G→A, which is predicted to result in the amino acid substitution p.G139R. Including our case, 4 families have been described as having PLS with MM, 3 of which are Japanese, implying a high incidence of melanoma development in Japanese PLS patients. We suggest that hereditary palmoplantar keratoderma (PPK) in Japanese patients might be predisposed to MM. A literature review revealed that in 18 cases of MM-associated PPK, 13 (76%) were Japanese, suggesting a high incidence of MM in Japanese PPK patients. This tendency might be attributable to the high frequency of acral lentiginous melanoma in Japanese subjects, in contrast to a lower frequency of this subtype in Caucasians.

Keywords:
Papillon-Lefèvre syndrome, Palmoplantar keratoderma, Malignant melanoma, Genodermatosis
1.
Verma KC, Chaddha MK, Joshi RK: Papillon-Lefèvre syndrome. Int J Dermatol 1979;18:146–149.
2.
Gorlin RJ, Sedano H, Anderson VE: The syndrome of palmar-plantar hyperkeratosis and premature periodontal destruction of the teeth: a clinical and genetic analysis of the Papillon-Lefèvre syndrome. J Pediatr 1964;65:895–908.
3.
Rao NV, Rao GV, Hoidal JR: Human dipeptidyl-peptidase I: gene characterization, localization, and expression. J Biol Chem 1997;272:10260–10265.
4.
Haneke E: The Papillon-Lefèvre syndrome: keratosis palmoplantaris with periodontopathy. Hum Genet 1979;51:1–35.
5.
Hacham-Zadeh S, Goldberg L: Malignant melanoma and Papillon-Lefèvre syndrome. Arch Dermatol 1982;118:2.
6.
Nakano A, Nomura K, Nakano H, Ono Y, LaForgia S, Pulkkinen L, Hashimoto I, Uitto J: Papillon-Lefèvre syndrome: mutations and polymorphisms in the cathepsin C gene. J Invest Dermatol 2001;116:339–343.
7.
Zhang Y, Hart PS, Moretti AJ, Bouwsma OJ, Fisher EM, Dudlicek L, Pettenati MJ, Hart TC: Biochemical and mutational analyses of the cathepsin C gene (CTSC) in three North American families with Papillon Lefèvre syndrome. Hum Mutat 2002;20:75.
8.
Shimoura A, Funasaka Y, Tsujishita Y, et al: A case of Papillon-Lefèvre syndrome associated with malignant melanoma and psychosis (in Japanese). Hifu Rinsho 1997;39:759–762.
9.
Kitami Y, Nakayama R, Harada S, Kitami A, Sueki H, Iijima M: A case of Papillon-Lefèvre syndrome associated with ALM in situ (in Japanese). Proc 17th Conf Disord Keratinization, Tokyo, 2002, vol 17, pp 86–88.
10.
Ishihara K: Epidemiology and prognostic factors of malignant melanoma; in Saida T, Yamamoto A (eds): Diagnosis and Treatment of Malignant Melanoma, ed 1 (in Japanese). Tokyo, Kanehara & Co., 2001, pp 12–20.
11.
Shimizu Y, Ohkuni T: A case of Meleda disease associated with malignant melanoma (in Japanese). Hifubyo-Zusetsu 1959;1:13–20.
12.
Matsuda H, Kawatsu T: A case of malignant melanoma arising in a brother of hereditary palmoplantar keratoderma (in Japanese). Hifubyo-Shinryo 1979;1:531–534.
13.
Okada T, Kawatsu Y, Ukon K, Ishihara Y: Lentigo maligna developing in Meleda-type palmoplantar keratoderma (in Japanese). Nishinihon J Dermatol 1979;41:249–253.
14.
Kaminaga T, Yonezawa I: Vörner type palmoplantar keratoderma associated with malignant melanoma (abstract, in Japanese). Jpn J Dermatol 1984;94:756.
15.
Urmacher C, Shiu MH: Malignant melanoma in association with keratosis palmaris et plantaris (epidermolytic hyperkeratosis variant). Am J Dermatopathol 1985;7 (suppl):187–190.
16.
Arisu K, Ogino Y, Suzuki M, Matsunaga K, Hayakawa R, Sugiura I, Hara K: A case of malignant melanoma associated with palmoplantar keratoderma (in Japanese). Skin Cancer 1991;6:375–379.
17.
Seike T, Nakanishi H, Urano Y, Arase S: Malignant melanoma developing in an area of palmoplantar keratoderma (Greither’s disease). J Dermatol 1995;22:55–61.
18.
Kato Y, Yamaguchi A, Orikasa R, Kikuchi S, Tateshita T, Ohtsuka M, Iwatsuki K, Ono I, Kaneko F: Three cases of malignant melanoma associated with palmoplantar keratoderma (in Japanese). Proc 14th Conf Disord Keratinization 1999, vol 14, pp 67–70.
19.
Ishida S, Yamakage A, Yamazaki S: A case of malignant melanoma in situ on the sole associated with palmoplantar keratoderma (in Japanese). Rinsho Derma 2001;55:534–536.
20.
Mozzillo N, Nunziata CA, Caraco C, Fazioli F, Botti G: Malignant melanoma developing in an area of hereditary palmoplantar keratoderma (Mal de Meleda). J Surg Oncol 2003;84:229–233.
21.
Dessureault F, Poulin Y, Bourcier M, Gagne E: Olmsted syndrome – palmoplantar and periorificial keratodermas: association with malignant melanoma. J Cutan Med Surg 2003;7:236–242.
22.
Rubegni P, Poggiali S, Cuccia A, Biagioli M, Fimiani M: Acral malignant melanoma and striated palmoplantar keratoderma (Brünauer-Fuhs-Siemens syndrome): a fortuitous association? Dermatol Surg 2004;30:1539–1542.
23.
Ishihara K, Saida T, Yamamoto T: Updated statistical data for malignant melanoma in Japan. Int J Clin Oncol 2001;6:109–116.
24.
Phan A, Touzet S, Dalle S, Ronger-Savle S, Balme B, Thomas L: Acral lentiginous melanoma: a clinicoprognostic study of 126 cases. Dermatology 2006;155:561–569.
25.
Yoshizaki Y, Kanki H, Ueda T, Ichihashi M, Ueda M: A further case of plantar squamous cell carcinoma arising in Olmsted syndrome. Br J Dermatol 2001;145:685–686.
26.
Ito T, Shiraishi S, Sayama K, Miki Y: Mal de Meleda-like palmoplantar keratoderma. J Dermatol 1991;18:43–46.
27.
Delaporte E, N’guyen-Mailfer C, Janin A, Savary JB, Vasseur F, Feingold N, Piette F, Bergoend H: Keratoderma with scleroatrophy of the extremities or sclerotylosis (Huriez syndrome): a reappraisal. Br J Dermatol 1995;133:409–416.
28.
Richtig E, Berghold A, Schwantzer G, Ott A, Wölfelmaier F, Karner B, Ludwig R, Denk H, Stering R, Leitner G, Lax S, Okcu M, Gerger A, Kerl H, Smolle J: Clinical epidemiology of invasive cutaneous malignant melanoma in the Austrian province Styria in the years 2001–2003 and its relationship with local geographical, meteorological and economic data. Dermatology 2007;214:246–252.
© 2008 S. Karger AG, Basel
2008
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.